loading
Schlusskurs vom Vortag:
$15.26
Offen:
$15.26
24-Stunden-Volumen:
32,851
Relative Volume:
0.35
Marktkapitalisierung:
$13.32B
Einnahmen:
$630.20M
Nettoeinkommen (Verlust:
$37.73M
KGV:
76.42
EPS:
0.2
Netto-Cashflow:
$-17.44M
1W Leistung:
+10.04%
1M Leistung:
+2.93%
6M Leistung:
-10.40%
1J Leistung:
-17.11%
1-Tages-Spanne:
Value
$15.02
$15.39
1-Wochen-Bereich:
Value
$13.39
$15.39
52-Wochen-Spanne:
Value
$11.51
$21.50

Hutchmed China Limited Adr Stock (HCM) Company Profile

Name
Firmenname
Hutchmed China Limited Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1,811
Name
Twitter
@hchimed
Name
Nächster Verdiensttermin
2025-03-19
Name
Neueste SEC-Einreichungen
Name
HCM's Discussions on Twitter

Vergleichen Sie HCM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
HCM
Hutchmed China Limited Adr
15.29 2.37B 630.20M 37.73M -17.44M 0.20
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.07 50.98B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
169.78 74.41B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.935 4.03M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.93 46.23B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.55 20.10B 16.54B -1.64B 749.00M -1.45

Hutchmed China Limited Adr Stock (HCM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-05-13 Herabstufung HSBC Securities Buy → Hold
2023-11-24 Hochstufung Deutsche Bank Hold → Buy
2022-05-04 Herabstufung Deutsche Bank Buy → Hold
2021-09-22 Herabstufung Goldman Buy → Neutral
2021-08-03 Eingeleitet Jefferies Buy
2020-10-02 Eingeleitet Deutsche Bank Buy
2020-03-13 Eingeleitet Cantor Fitzgerald Overweight
2020-02-20 Eingeleitet Goldman Buy
2019-11-19 Eingeleitet CLSA Buy
2019-10-23 Bestätigt BofA/Merrill Buy
2019-07-05 Eingeleitet Macquarie Outperform
Alle ansehen

Hutchmed China Limited Adr Aktie (HCM) Neueste Nachrichten

pulisher
Jun 05, 2025

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High? - sharewise

Jun 05, 2025
pulisher
Jun 05, 2025

Market news - investments.halifax.co.uk

Jun 05, 2025
pulisher
Jun 04, 2025

Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Renal Cell Carcinoma - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

HUTCHMED and Innovent Jointly Announce NDA Acceptance in - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma - GlobeNewswire Inc.

Jun 04, 2025
pulisher
Jun 04, 2025

Northern Trust Corp Sells 10,700 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jun 04, 2025
pulisher
Jun 01, 2025

Millennium Management LLC Sells 100,366 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jun 01, 2025
pulisher
May 26, 2025

D. E. Shaw & Co. Inc. Trims Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 26, 2025
pulisher
May 24, 2025

BNP Paribas Financial Markets Trims Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 24, 2025
pulisher
May 20, 2025

Jane Street Group LLC Grows Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 20, 2025
pulisher
May 16, 2025

Barclays PLC Purchases 2,255 Shares of HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

May 16, 2025
pulisher
May 16, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times

May 16, 2025
pulisher
May 15, 2025

UPDATEInternational companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Globe and Mail

May 15, 2025
pulisher
May 13, 2025

International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on May 15, 2025 - The Manila Times

May 13, 2025
pulisher
May 09, 2025

International companies to host live webcasts at Deutsche - GlobeNewswire

May 09, 2025
pulisher
May 06, 2025

HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in SAVANNAH Phase II Trial - Barchart.com

May 06, 2025
pulisher
May 05, 2025

Marshall Wace LLP Acquires New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - The AM Reporter

May 05, 2025
pulisher
Apr 29, 2025

CN Reportedly Directs Pharmas, Hospitals to Study Feasibility of Substituting US Imported Products - AASTOCKS.com

Apr 29, 2025
pulisher
Apr 23, 2025

RCSHutchmed China LtdHUTCHMEDData to be Presented at AACR 2025 - TradingView

Apr 23, 2025
pulisher
Apr 21, 2025

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China - Yahoo Finance

Apr 21, 2025
pulisher
Mar 24, 2025

HUTCHMEDOncology portfolio growth expected to continue - Research Tree

Mar 24, 2025
pulisher
Mar 23, 2025

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Sold by Connor Clark & Lunn Investment Management Ltd. - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Richard Li Invited to Attend China Development Forum, Pictured with Li Qiang and Others - AASTOCKS.com

Mar 23, 2025
pulisher
Mar 20, 2025

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees - GlobeNewswire

Mar 20, 2025
pulisher
Mar 19, 2025

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 18, 2025

Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 - GlobeNewswire

Mar 18, 2025
pulisher
Mar 09, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 - AsiaOne

Mar 09, 2025
pulisher
Feb 20, 2025

HUTCHMED (HCM) Upgraded to Buy: Here's Why - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Wall Street Analysts Believe HUTCHMED (HCM) Could Rally 72.83%: Here's is How to Trade - Yahoo Finance

Feb 20, 2025
pulisher
Feb 19, 2025

CN NMPA Guides Pharmas, Research Institutes to Enlarge R&D of Innovative Drugs, High-Quality Generic Drugs - AASTOCKS.com

Feb 19, 2025
pulisher
Feb 17, 2025

ABC Arbitrage SA Buys New Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - MarketBeat

Feb 17, 2025
pulisher
Feb 04, 2025

Sea Limited Sponsored ADR (SE) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance

Feb 04, 2025
pulisher
Jan 28, 2025

Crossmark Global Holdings Inc. Increases Stock Position in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Jan 28, 2025
pulisher
Jan 16, 2025

CN Healthcare Fund Breaks even w/ Slim Surplus in 2024 - AASTOCKS.com

Jan 16, 2025
pulisher
Jan 13, 2025

HUTCHMED Announces NMPA Full Approval for - GlobeNewswire

Jan 13, 2025
pulisher
Jan 07, 2025

UBS Trims HUTCHMED (00013.HK)TP to $38.7 w/ Rating Buy - AASTOCKS.com

Jan 07, 2025
pulisher
Jan 05, 2025

Private equity firms are HUTCHMED (China) Limited's (LON:HCM) biggest owners and were rewarded after market cap rose by UK£120m last week - Yahoo Finance

Jan 05, 2025
pulisher
Jan 05, 2025

HSBC Global Research Prefers BeiGene/ SINO BIOPHARM/ HYGEIA HEALTH Given Higher Visibility in CN Pharma & Medical Device Subsectors - AASTOCKS.com

Jan 05, 2025
pulisher
Jan 02, 2025

Hutchmed announces progress, hits milestone with lung cancer treatment - ShareCast

Jan 02, 2025
pulisher
Jan 02, 2025

Savolitinib Plus Osimertinib Receives Priority Review in China for Pretreated EGFR+ NSCLC With a MET Amplification - OncLive

Jan 02, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority Review Status for ORPATHYS® and TAGRISSO® Combination in Lung Cancer Patients with MET amplification After Progression on First-Line EGFR Inhibitor Therapy - The Manila Times

Jan 01, 2025
pulisher
Jan 01, 2025

HUTCHMED Announces NDA Acceptance in China with Priority - GlobeNewswire

Jan 01, 2025
pulisher
Dec 29, 2024

Jane Street Group LLC Raises Stock Holdings in HUTCHMED (China) Limited (NASDAQ:HCM) - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

HUTCHMED (China) Limited (NASDAQ:HCM) Shares Purchased by State Street Corp - Defense World

Dec 28, 2024
pulisher
Dec 12, 2024

HCMHUTCHMED (China) Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan

Dec 12, 2024
pulisher
Dec 12, 2024

HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients After Disease Progression on EGFR Inhibitor Therapy - The Manila Times

Dec 12, 2024
pulisher
Dec 11, 2024

HUTCHMED Announces Breakthrough Therapy Designation in - GlobeNewswire

Dec 11, 2024

Finanzdaten der Hutchmed China Limited Adr-Aktie (HCM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
drug_manufacturers_specialty_generic RDY
$15.46
price down icon 0.45%
$126.55
price up icon 0.95%
$324.00
price down icon 0.79%
$8.595
price up icon 1.77%
$17.51
price up icon 1.54%
Kapitalisierung:     |  Volumen (24h):